Mer­ck to face FDA ad­comm in No­vem­ber over pre­vi­ous­ly re­ject­ed po­ten­tial chron­ic cough drug

The FDA an­nounced this morn­ing that on Nov. 17 it will hold an ad­vi­so­ry com­mit­tee meet­ing to take an­oth­er look at Mer­ck’s gefapix­ant for chron­ic cough.

While Eu­ro­pean reg­u­la­tors signed off on gefapix­ant in Ju­ly, the oral tablets ran in­to a com­plete re­sponse let­ter from FDA back in Jan­u­ary 2022, with the com­pa­ny say­ing FDA sought “ad­di­tion­al in­for­ma­tion re­lat­ed to mea­sure­ment of ef­fi­ca­cy. The CRL was not re­lat­ed to the safe­ty of gefapix­ant.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER